These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 340170)

  • 1. Silver sulfadiazine: lack of mutagenic activity.
    McCoy EC; Rosenkranz HS
    Chemotherapy; 1978; 24(2):87-91. PubMed ID: 340170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo and in vitro antimicrobial activity of silver sulfadiazine and cerium nitrate.
    Saffer LD; Rodeheaver GT; Hiebert JM; Edlich RF
    Surg Gynecol Obstet; 1980 Aug; 151(2):232-6. PubMed ID: 6773164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of sulfadiazine compounds of zinc and silver.
    Nagesha CN
    Arch Surg; 1978 Jul; 113(7):906. PubMed ID: 678109
    [No Abstract]   [Full Text] [Related]  

  • 4. The determination of the susceptibility of bacterial isolates to silver sulfadiazine.
    Rosenkranz HS; Carr HS
    Chemotherapy; 1978; 24(3):143-5. PubMed ID: 657875
    [No Abstract]   [Full Text] [Related]  

  • 5. Method to determine antibacterial activity of silver sulfadiazine creams.
    Klein S; Lentsch RH; Christoffersen G
    J Burn Care Rehabil; 1986; 7(5):382-4. PubMed ID: 3095328
    [No Abstract]   [Full Text] [Related]  

  • 6. Silver sulfadiazine (AgSD) resistant pseudomonas infection in experimental burn wounds.
    Modak SM; Stanford JW; Bradshaw W; Fox CL
    Panminerva Med; 1983; 25(3):181-8. PubMed ID: 6669393
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhibition of adenosine triphosphatase in vitro by silver nitrate and silver sulfadiazine.
    Nechay BR; Saunders JP
    J Environ Pathol Toxicol Oncol; 1984 Jul; 5(4-5):119-26. PubMed ID: 6240533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of in vitro sensitivity to sulfadiazine silver.
    McManus AT; Denton CL; Mason AD
    Arch Surg; 1983 Feb; 118(2):161-6. PubMed ID: 6401421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology and clinical use of silver sulfadiazine and related topical antimicrobial agents.
    Fox CL
    Pahlavi Med J; 1977 Jan; 8(1):45-64. PubMed ID: 834468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of topical applications of silver sulfadiazine on the natural killer cell activity in a rat model of thermal injury.
    Singh H; Berg N; Herndon DN
    J Burn Care Rehabil; 1988; 9(2):152-5. PubMed ID: 3360817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response of varicella zoster virus and herpes zoster to silver sulfadiazine.
    Montes LF; Muchinik G; Fox CL
    Cutis; 1986 Dec; 38(6):363-5. PubMed ID: 3026736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carcinogenicity and mutagenicity of N-nitroso compounds.
    Lijinsky W
    Mol Toxicol; 1987; 1(1):107-19. PubMed ID: 3329700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assay of 855 test chemicals in ten tester strains using a new modification of the Ames test for bacterial mutagens.
    McMahon RE; Cline JC; Thompson CZ
    Cancer Res; 1979 Mar; 39(3):682-93. PubMed ID: 371791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SOS chromotest results in a broader context: empirical relationships between genotoxic potency, mutagenic potency, and carcinogenic potency.
    White PA; Rasmussen JB
    Environ Mol Mutagen; 1996; 27(4):270-305. PubMed ID: 8665872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rat hepatocyte-mediated bacterial mutagenicity in relation to the carcinogenic potency of benz(a)anthracene, benzo(a)pyrene, and twenty-five methylated derivatives.
    Utesch D; Glatt H; Oesch F
    Cancer Res; 1987 Mar; 47(6):1509-15. PubMed ID: 3545447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure activity studies with N-nitrosamines using Salmonella typhimurium and Escherichia coli.
    Rao TK; Epler JL; Lijinsky W
    IARC Sci Publ; 1982; (41):543-51. PubMed ID: 6754596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The proportions of mutagens among chemicals in commerce.
    Zeiger E; Margolin BH
    Regul Toxicol Pharmacol; 2000 Oct; 32(2):219-25. PubMed ID: 11067778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, physical properties and microbiological activities of more water soluble silver sulfadiazine derivatives.
    De Wit PP; Van Doorne H; Bult A
    Pharm Weekbl Sci; 1983 Dec; 5(6):298-301. PubMed ID: 6664822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutagenic activity of chemicals previously tested for carcinogenicity in the National Cancer Institute bioassay program.
    Dunkel VC; Simmon VF
    IARC Sci Publ; 1980; (27):283-301. PubMed ID: 7002779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carcinogenicity of mutagens: predictive capability of the Salmonella mutagenesis assay for rodent carcinogenicity.
    Zeiger E
    Cancer Res; 1987 Mar; 47(5):1287-96. PubMed ID: 3815340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.